AbbVie announces provincial reimbursement for Rinvoq (upadacitinib) for the treatment of rheumatoid arthritis and psoriatic arthritis in Alberta, New Brunswick, Ontario, Quebec and Saskatchewan

1 December 2022 - AbbVie today announced that Rinvoq is now listed as a special authorisation medication or exception medication status ...

Read more →

Alberta expands access to cystic fibrosis drug Trikafta for children 6 to 11

11 July 2022 - Children with cystic fibrosis can now live 'longer, healthier and fuller lives,' says advocate. ...

Read more →

Boehringer Ingelheim Canada announces reimbursement for Ofev (nintedanib) in seven public drug plans for the treatment of progressive fibrosing interstitial lung diseases

3 May 2022 - Boehringer Ingelheim is pleased to announce that Ofev (nintedanib), is now available for public reimbursement in Quebec, ...

Read more →

Baqsimi (nasal glucagon), rescue treatment for severe hypoglycaemia now covered in British Colombia, Alberta & Saskatchewan

27 April 2022 - Lilly Canada is pleased to announce that as of 5 April 2022, Baqsimi (glucagon nasal powder) ...

Read more →

Astellas announces reimbursement for Xospata (gilteritinib) in most provinces for patients with relapsed or refractory acute myeloid leukaemia with a FLT3 mutation

21 April 2022 - Having access to an additional treatment option offers hope for Canadian adult AML patients with relapsed ...

Read more →

Teva Canada welcomes public drug plan reimbursement by Alberta, Saskatchewan, Québec, Veteran Affairs Canada and the non-insured health benefits program for patients prescribed Ajovy (fremanezumab) for the preventive treatment of migraine in adults

2 March 2022 - Public formulary and program coverage makes AJOVY® accessible to more migraine patients across Canada. ...

Read more →

AbbVie announces provincial reimbursement for Venclexta (venetoclax) with obinutuzumab for patients with previously untreated chronic lymphocytic leukaemia in Alberta, Saskatchewan, British Columbia and Manitoba

24 February 2022 - AbbVie announced today that Alberta, Saskatchewan, British Columbia, and Manitoba now reimburse Venclexta (venetoclax) in combination ...

Read more →

Valeo Pharma obtains public reimbursement for Enerzair Breezhaler and Atectura Breezhaler in Alberta

3 November 2021 - First provincial public listing secured for both asthma medications. ...

Read more →

Alberta faces shortage of COVID-19 drug as global demand spikes

11 May 2021 - Provinces with highest case rates hit by shortage of medication for sickest patients. ...

Read more →

Alberta, Canada, begins mandating switches from originator to biosimilar Humira

6 May 2021 - Alberta, Canada becomes the latest province to begin switching patients from originator adalimumab (Humira) to biosimilar ...

Read more →

Kite's Yescarta (axicabtagene ciloleucel) reimbursed in Alberta for the treatment of certain types of aggressive non-Hodgkin lymphoma

23 April 2021 - Gilead Canada announced today that Yescarta (axicabtagene ciloleucel) is now available in Alberta as a treatment ...

Read more →

Alberta family waiting on approval for expensive, life-saving drug for young boy

23 March 2021 - Reign Johnston turned 2 on March 5. One of his grandpas and an uncle came to ...

Read more →

Pay for plasma collection coming to Alberta by end of the year

14 February 2021 - Repeal of NDP bill last fall clears way for Canadian Plasma Resources to set up shop. ...

Read more →

Alberta announces funding for pricey gene therapy drug Zolgensma

Alberta Health Minister Tyler Shandro announced funding Wednesday for the gene therapy Zolgensma, which is used to treat toddlers with ...

Read more →

Alberta, Canada sees early success from switching patients to biosimilars

5 November 2020 - Following the launch of its Biosimilars Initiative in December 2019, Alberta, Canada, has succeeded in switching 16% ...

Read more →